As MEDSIR prepares to make its debut at SCOPE Summit 2026, the leading global forum for innovation in clinical operations, the company is highlighting its commitment to accelerating and optimizing clinical development for biotech and pharma innovators. With the industry facing increasing pressure to deliver faster, smarter, and more efficient clinical trials, MEDSIR enters SCOPE with a clear message: ‘Upgrading your pipeline. Faster.’ In this internal interview, Laura Calabuig, Business Developm

MEDSIR, a leading international company in oncology research, has announced the results of the PHERGuide study during the 2025 San Antonio Breast Cancer Symposium (SABCS). This research, presented as an oral session during the congress, corresponds to a translational analysis of the PHERGain study and evaluates the correlation between the presence of circulating tumor DNA (ctDNA) in the blood, with the response to treatment and the risk of recurrence in patients with HER2+ early BC.

The EMPRESS study analyzes the potential benefit of giredestrant, a potent oral selective estrogen receptor degrader (SERD), in premenopausal women with early-stage ER+/HER2- breast cancer.  The results, presented during the ESMO 2025 congress, indicate a significant reduction in tumor markers compared to the current standard therapy.  These findings pave the way for exploring endocrine therapy-based strategies in premenopausal women without the need for ovarian function suppression,...